AIM: To analyze the serum levels of retinoids and Leiden mutation in patients with esophageal, gastric, liver, pancreatic, and colorectal cancers. METHODS: The changes in serum levels of retinoids (vitamin A, alpha- and beta-carotene, alpha- and beta-cryptoxanthin, zeaxanthin, lutein) and Leiden mutation were measured by high liquid performance chromatography (HPLC) and polymerase chain reaction (PCR) in 107 patients (70 males/37 females) with esophageal (0/8), gastric (16/5), liver (8/7), pancreatic (6/4), and colorectal (30/21 including 9 patients suffering from in situ colon cancer) cancer. Fifty-seven healthy subjects (in matched groups) for controls of serum retinoids and 600 healthy blood donors for Leiden mutation were used. RESULTS: The serum levels of vitamin A and zeaxanthin were decreased significantly in all groups of patients with gastrointestinal (GI) tumors except for vitamin A in patients with pancreatic cancer. No changes were obtained in the serum levels of alpha- and beta-carotene, alpha- and beta-cryptoxanthin, zeaxanthin, lutein in patients with GI cancer. The prevalence of Leiden mutation significantly increased in all groups of patients with GI cancer. CONCLUSION: Retinoids (as environmental factors) are decreased significantly with increased prevalence of Leiden mutation (as a genetic factor) in patients before the clinical manifestation of histologically different (planocellular and hepatocellular carcinoma, and adenocarcinoma) GI cancer.
AIM: To analyze the serum levels of retinoids and Leiden mutation in patients with esophageal, gastric, liver, pancreatic, and colorectal cancers. METHODS: The changes in serum levels of retinoids (vitamin A, alpha- and beta-carotene, alpha- and beta-cryptoxanthin, zeaxanthin, lutein) and Leiden mutation were measured by high liquid performance chromatography (HPLC) and polymerase chain reaction (PCR) in 107 patients (70 males/37 females) with esophageal (0/8), gastric (16/5), liver (8/7), pancreatic (6/4), and colorectal (30/21 including 9 patients suffering from in situ colon cancer) cancer. Fifty-seven healthy subjects (in matched groups) for controls of serum retinoids and 600 healthy blood donors for Leiden mutation were used. RESULTS: The serum levels of vitamin A and zeaxanthin were decreased significantly in all groups of patients with gastrointestinal (GI) tumors except for vitamin A in patients with pancreatic cancer. No changes were obtained in the serum levels of alpha- and beta-carotene, alpha- and beta-cryptoxanthin, zeaxanthin, lutein in patients with GI cancer. The prevalence of Leiden mutation significantly increased in all groups of patients with GI cancer. CONCLUSION:Retinoids (as environmental factors) are decreased significantly with increased prevalence of Leiden mutation (as a genetic factor) in patients before the clinical manifestation of histologically different (planocellular and hepatocellular carcinoma, and adenocarcinoma) GI cancer.
Authors: G Mózsik; B Bódis; M Figler; A Király; O Karádi; A Pár; G Rumi; G Sütõ; G Tóth; A Vincze Journal: Life Sci Date: 2001-11-09 Impact factor: 5.037
Authors: R M Bertina; B P Koeleman; T Koster; F R Rosendaal; R J Dirven; H de Ronde; P A van der Velden; P H Reitsma Journal: Nature Date: 1994-05-05 Impact factor: 49.962
Authors: Olga V Gran; Erin N Smith; Sigrid K Brækkan; Hilde Jensvoll; Terry Solomon; Kristian Hindberg; Tom Wilsgaard; Frits R Rosendaal; Kelly A Frazer; John-Bjarne Hansen Journal: Haematologica Date: 2016-06-16 Impact factor: 9.941
Authors: Brian Turpin; Whitney Miller; Leah Rosenfeldt; Keith Kombrinck; Matthew J Flick; Kris A Steinbrecher; Eleana Harmel-Laws; Eric S Mullins; Maureen Shaw; David P Witte; Alexey Revenko; Brett Monia; Joseph S Palumbo Journal: Cancer Res Date: 2014-04-07 Impact factor: 12.701
Authors: Mari Tinholt; Marte Kathrine Viken; Anders Erik Dahm; Hans Kristian Moen Vollan; Kristine Kleivi Sahlberg; Oystein Garred; Anne-Lise Børresen-Dale; Anne Flem Jacobsen; Vessela Kristensen; Ida Bukholm; Rolf Kåresen; Ellen Schlichting; Grethe Skretting; Benedicte Alexandra Lie; Per Morten Sandset; Nina Iversen Journal: BMC Cancer Date: 2014-11-19 Impact factor: 4.430
Authors: Ming-Chao Bi; Richard Rosen; Ren-Yuan Zha; Steven A McCormick; E Song; Dan-Ning Hu Journal: Evid Based Complement Alternat Med Date: 2013-10-10 Impact factor: 2.629